Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
Mirikizumab, Crohn’s disease
JOURNALS
Start Learning
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
touchEXPERT BRIEFING
Start Learning
UCB, making a difference in immunology
Sponsored content
JOURNALS
Start Learning
A Career in Endoscopy: 5 insights from UEG Lifetime Achievement Awardee – Paul Fockens
www.touchimmunology.com
JOURNALS
Start Learning
FDA approves bimekizumab for psoriatic arthritis, ankylosing spondylitis and axSpA
CONFERENCE HUB
Start Learning
Efficacy and safety of izokibep: An investigational IL-17A inhibitor
Musculoskeletal AI image
JOURNALS
Start Learning
Artificial Intelligence in Musculoskeletal Medicine: A Scoping Review
JOURNALS
Start Learning
New study reveals elevated cognitive impairment risk in rheumatoid arthritis patients, linked to inflammation and comorbidities
journal placeholder
JOURNALS
Start Learning
Novel anti-CD6 monoclonal antibody, itolizumab, showcases proof of concept in ulcerative colitis
3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
JOURNALS
Start Learning
Clinical Approach to the Care of Patients with Immune Checkpoint Inhibitor-associated Inflammatory Arthritis
RMDs: Experts tell you what to expect in 2025
JOURNALS
Start Learning
RMDs: What to Expect in 2025

to view Favourites, Keep Notes and Track CME Credits

Favourites
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
View
Advances in the treatment of lupus and Sjögren’s disease
View
Key data on pain and prognosis: Clinical insights and implications
View
Increased infliximab clearance in patients hospitalized with severe ulcerative colitis may lead to underexposure
View
Efficacy and safety of izokibep: An investigational IL-17A inhibitor
View
Highlights from EULAR 2024: Advancing rheumatology
View
Breakthroughs in MASH: Highlights from EASL 2024
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025
View
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup